Belite Bio, Inc (BLTE) shareholders
BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
$164.35−5.61 (-3.30%)
Close on Nov 13, 2026Market cap $6.47BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
24.1%
9M of 39M shares
Institutional holders
81
22 new, 16 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 175 sales
Net sold $40.63M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lin Bioscience International Ltd. | 17,095,263 | 53.70% | 13G (passive) | Dec 31, 2024 |
| Trehan Abhishek Joint filing with Darwin Global Management, Ltd. (8.10%), Darwin Global Master Fund, Ltd. (7.80%) | 3,027,704 | 8.10% | 13G (passive) amendment | Dec 31, 2025 |
| Dr. Abhishek Trehan Joint filing with Darwin Global Management, Ltd. (7.00%), Darwin Global Master Fund, Ltd. (6.70%) | 2,617,094 | 7.00% | 13G (passive) | Dec 3, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BLTE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | 3,077,219 | 7.82% | $456.59M | +19,807 | 12.14% |
| Paradigm Biocapital Advisors LP | 1,232,877 | 3.13% | $189.84M | +118,093 | 3.55% |
| Rtw Investments, LP | 715,332 | 1.82% | $110.15M | – | 0.94% |
| Millennium Management LLC | 494,564 | 1.26% | $76.16M | −75,524 | 0.03% |
| Maverick Capital Ltd | 396,311 | 1.01% | $61.03M | New | 0.54% |
| Eventide Asset Management, LLC | 390,829 | 0.99% | $60.18M | +33,179 | 0.80% |
| Deerfield Management Company, L.P. (Series C) | 357,199 | 0.91% | $55.00M | +53,186 | 0.57% |
| Holocene Advisors, LP | 251,035 | 0.64% | $38.66M | −243,460 | 0.09% |
| Logos Global Management LP | 250,000 | 0.64% | $38.50M | New | 1.66% |
| Morgan Stanley | 235,071 | 0.60% | $36.20M | +33,662 | 0.00% |
| UBS Group AG | 224,989 | 0.57% | $34.64M | −543,370 | 0.00% |
| Citadel Advisors LLC | 186,168 | 0.47% | $28.67M | +184,160 | 0.00% |
| Goldman Sachs Group Inc | 166,188 | 0.42% | $25.59M | +60,679 | 0.00% |
| Affinity Asset Advisors, LLC | 165,000 | 0.42% | $25.41M | +100,000 | 1.15% |
| Mpm Bioimpact LLC | 137,208 | 0.35% | $21.13M | +49,163 | 1.29% |
| Bank Of America Corp /De/ | 124,783 | 0.32% | $19.21M | +121,005 | 0.00% |
| Patient Square Capital LP | 110,000 | 0.28% | $16.94M | −6,684 | 2.62% |
| Duquesne Family Office LLC | 106,100 | 0.27% | $16.34M | – | 0.31% |
| Price T Rowe Associates Inc /Md/ | 105,859 | 0.27% | $16.30M | −175,946 | 0.00% |
| Jane Street Group, LLC | 65,801 | 0.17% | $10.13M | +53,579 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 81 | 9M | 24.1% | 22 / 28 | 22 / 16 | 2M | 1M |
| Q1 2026 | 75 | 9M | 23.2% | 28 / 26 | 15 / 21 | 3M | 1M |
| Q4 2025 | 69 | 7M | 18.3% | 40 / 17 | 10 / 4 | 6M | 1M |
| Q3 2025 | 34 | 2M | 5.8% | 16 / 12 | 5 / 0 | 2M | 0M |
| Q2 2025 | 18 | 0M | 0.2% | 6 / 6 | 5 / 6 | 0M | 0M |
| Q1 2025 | 18 | 0M | 0.4% | 7 / 5 | 5 / 11 | 0M | 0M |
| Q4 2024 | 22 | 0M | 0.7% | 9 / 6 | 5 / 2 | 0M | 0M |
| Q3 2024 | 15 | 0M | 0.2% | 6 / 5 | 2 / 2 | 0M | 0M |
| Q2 2024 | 11 | 0M | 0.5% | 2 / 2 | 6 / 2 | 0M | 0M |
| Q1 2024 | 11 | 0M | 0.2% | 0 / 2 | 8 / 6 | 0M | 0M |
| Q4 2023 | 17 | 0M | 0.5% | 12 / 3 | 1 / 2 | 0M | 0M |
| Q3 2023 | 7 | 0M | 0.3% | 3 / 2 | 1 / 2 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
24 funds held BLTE in Q2 2026, 9% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BLTE | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 80,462 | 0.20% | $12.39M | 0.10% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 62,205 | 0.16% | $9.58M | 0.54% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio Emerging Markets ETF | 12,456 | 0.03% | $1.92M | 0.01% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 6,727 | 0.02% | $969.90K | 0.00% | May 31, 2026 |
| Fidelity ZERO International Index Fund | 5,934 | 0.02% | $941.19K | 0.01% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Portfolio | 5,400 | 0.01% | $831.52K | 0.11% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index ETF | 3,734 | 0.01% | $538.37K | 0.00% | May 31, 2026 |
| ActivePassive International Equity ETF | 3,713 | 0.01% | $535.34K | 0.05% | May 31, 2026 |
| Select Biotechnology Portfolio | 3,100 | 0.01% | $446.96K | 0.01% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) China ETF | 3,068 | 0.01% | $472.43K | 0.11% | Jun 30, 2026 |
| Virtus Biotech Clinical Trials Etf | 2,250 | 0.01% | $356.87K | 0.77% | Jul 31, 2026 |
| Fidelity Flex International Index Fund | 2,090 | 0.01% | $331.49K | 0.01% | Jul 31, 2026 |
| Health Sciences Trust | 1,800 | 0.00% | $277.17K | 0.11% | Jun 30, 2026 |
| EQ/T.Rowe Price Health Sciences Portfolio | 1,400 | 0.00% | $215.58K | 0.12% | Jun 30, 2026 |
| Even Herd Long Short ETF | 1,282 | 0.00% | $197.41K | 0.33% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Hao-Yuan Chuang | Chief Financial Officer, Director | 210,264 | 0.53% | Oct 30, 2026 |
| Yu-Hsin Lin | Chief Executive Officer, Director | 187,949 | 0.48% | Oct 30, 2026 |
| Hendrik Peter Scholl | Chief Medical Officer | 14,500 | 0.04% | Oct 5, 2026 |
| Nathan L. Mata | Chief Scientific Officer | 440 | 0.00% | May 8, 2026 |
| Wan-Shan Chen | Director | 37,259 | 0.09% | Oct 30, 2026 |
| Xiao-Hui Chen | Director | 400 | 0.00% | Mar 18, 2026 |
| Ita Lu | Director | – | – | Mar 18, 2026 |
| John Michael Longo | Director | – | – | Mar 18, 2026 |
| Gary Clark Biddle | Director | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Hao-Yuan Chuang Chief Financial Officer, Director | Oct 29, 2026 | Other | +5,000 | – | – | 180,264 |
| Yu-Hsin Lin Chief Executive Officer, Director | Oct 29, 2026 | Other | +5,000 | – | – | 187,949 |
| Hendrik Peter Scholl Chief Medical Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −2 | $170.02 | $340 | 14,500 |
| Hendrik Peter Scholl Chief Medical Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −14 | $169.36 | $2.37K | 14,502 |
| Hendrik Peter Scholl Chief Medical Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −12 | $168.21 | $2.02K | 14,516 |
| Hendrik Peter Scholl Chief Medical Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −78 | $167.59 | $13.07K | 14,528 |
| Hendrik Peter Scholl Chief Medical Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −50 | $166.44 | $8.32K | 14,606 |
| Hendrik Peter Scholl Chief Medical Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −120 | $165.49 | $19.86K | 14,656 |
| Hendrik Peter Scholl Chief Medical Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −24 | $164.64 | $3.95K | 14,776 |
| Hendrik Peter Scholl Chief Medical Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −200 | $163.63 | $32.73K | 14,800 |
| Wan-Shan Chen Director | Sep 24, 2026 | Option exercise | +13,796 | $0.44 | $6.05K | 37,259 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −6,090 | $195.62 | $1.19M | 87,644 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,400 | $194.33 | $466.39K | 93,734 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,700 | $198.09 | $534.84K | 70,134 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −8,752 | $197.36 | $1.73M | 72,834 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −6,058 | $196.54 | $1.19M | 81,586 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −4,605 | $197.23 | $908.24K | 28,600 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −4,475 | $196.47 | $879.20K | 33,205 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −4,120 | $195.60 | $805.87K | 37,680 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,200 | $194.28 | $427.42K | 41,800 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,562 | $198.05 | $507.40K | 26,038 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −4,209 | $192.54 | $810.40K | 104,245 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −11,080 | $191.15 | $2.12M | 108,454 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −600 | $190.39 | $114.23K | 119,534 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −8,955 | $189.34 | $1.70M | 120,134 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,045 | $188.26 | $573.25K | 129,089 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −6,200 | $187.25 | $1.16M | 132,134 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −7,800 | $186.32 | $1.45M | 138,334 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −4,593 | $185.34 | $851.27K | 146,134 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −6,252 | $184.52 | $1.15M | 150,727 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −4,955 | $183.30 | $908.25K | 156,979 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,413 | $182.50 | $622.87K | 161,934 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −2,587 | $181.24 | $468.87K | 165,347 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −2,635 | $180.29 | $475.06K | 167,934 |
| Yu-Hsin Lin Chief Executive Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −8,111 | $193.13 | $1.57M | 96,134 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −2,000 | $181.05 | $362.10K | 89,800 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −4,602 | $193.12 | $888.74K | 44,000 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,398 | $192.40 | $653.78K | 48,602 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −6,200 | $191.09 | $1.18M | 52,000 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −1,800 | $190.63 | $343.13K | 58,200 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −6,200 | $189.22 | $1.17M | 60,000 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −1,900 | $188.59 | $358.32K | 66,200 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,900 | $187.16 | $729.92K | 68,100 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −4,600 | $186.35 | $857.21K | 72,000 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,872 | $185.28 | $717.40K | 76,600 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,569 | $184.57 | $658.73K | 80,472 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −3,759 | $183.27 | $688.91K | 84,041 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −2,000 | $182.49 | $364.98K | 87,800 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Sep 4, 2026 | Sale(10b5-1 plan) | −1,633 | $180.16 | $294.20K | 91,800 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −223 | $180.57 | $40.27K | 93,433 |
| Hao-Yuan Chuang Chief Financial Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −144 | $180.00 | $25.92K | 93,656 |
| Yu-Hsin Lin Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −142 | $180.00 | $25.56K | 170,792 |
| Yu-Hsin Lin Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −223 | $180.57 | $40.27K | 170,569 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 18, 2026 | Sale | −96 | $143.90 | $13.81K | 24,904 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 18, 2026 | Sale | −4,861 | $145.43 | $706.94K | 16,295 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 18, 2026 | Sale | −1,199 | $146.24 | $175.34K | 15,096 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 18, 2026 | Sale | −96 | $147.11 | $14.12K | 15,000 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 18, 2026 | Sale | −3,748 | $144.66 | $542.19K | 21,156 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 16, 2026 | Sale | −1,897 | $143.55 | $272.31K | 26,035 |
| Hendrik Peter Scholl Chief Medical Officer | Jun 16, 2026 | Sale | −450 | $142.20 | $63.99K | 27,932 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
1M shares short
Days to cover
10.0
At 0M shares a day
Change since last report
+8.9%
From 1M shares
Short volume, 20 days
74.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Belite Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,744 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Hendrik Peter Scholl Officer | Oct 1, 2026 | 4,000 | $679.28K | Oct 1, 2026 | RSU Vesting |
| Hao-Yuan Chuang Officer, Director | Aug 12, 2026 | 93,800 | $16.66M | Aug 12, 2026 | ESOP Exercise |
| Yu-Hsin Lin CEO, Chairman | Aug 12, 2026 | 126,800 | $22.52M | Aug 12, 2026 | ESOP Exercise |
| Dr. Hendrick P. Scholl Affiliate | Jun 18, 2026 | 10,000 | $1.48M | Jun 18, 2026 | Vested RSUs |
| Dr. Hendrick P. Scholl Affiliate | Jun 16, 2026 | 10,000 | $1.44M | Jun 16, 2026 | Vested RSUs |
| Nathan L. Mata Officer | Apr 15, 2026 | 16,666 | $2.87M | Apr 15, 2026 | Stock Option Exercise |
| Hao-Yuan Chuang Officer, Director | Apr 9, 2026 | 100,000 | $17.87M | Apr 9, 2026 | ESOP Exercise |
| Yu-Hsin Lin CEO, Chairman | Apr 9, 2026 | 136,000 | $24.31M | Apr 9, 2026 | ESOP Exercise |
| Wan-Shan Chen affiliate | Apr 9, 2026 | 10,196 | $2.22M | Apr 9, 2026 | Exercise and Hold of Stock Options |
| Wan-Shan Chen Affiliate | Oct 17, 2025 | 9,550 | $1.16M | Oct 17, 2025 | NQ Stock Award |
| Wan-Shan Chen affiliate | Oct 16, 2025 | 1,050 | $89.25K | Oct 16, 2025 | NQ Stock Award |
| Wan-Shan Chen affiliate | Oct 14, 2025 | 1,050 | $84.00K | Oct 13, 2025 | NQ Stock Award |
| Hao-Yuan Chuang Officer, Director | Oct 14, 2025 | 70,054 | $5.59M | Oct 13, 2025 | Stock Option Exercise |
| Yu-Hsin Lin CEO, Chairman | Sep 18, 2025 | 96,950 | $7.08M | Sep 18, 2025 | Employee Stock Option Exercise |
| Nathan L. Mata Officer | Aug 21, 2025 | 30,000 | $1.90M | Aug 21, 2025 | Stock Option Exercise |
See a number that looks wrong?